Hims & Hers Shares Drop Sharply After Earnings Report

Hims & Hers stock fell sharply in premarket trading after the digital health company reported disappointing first-quarter financial results and cautious forward guidance. The telehealth company posted a net loss of $92 million for the quarter, widening significantly from the approximately $50 million loss recorded during the same period last year.

Adjusted EBITDA also declined substantially to $44 million from $91 million a year earlier, highlighting increasing pressure on profitability.
Revenue still grew modestly, rising 4% year over year to $608 million, though average monthly revenue per subscriber declined from $85 to $80.
The earnings report triggered a strong negative reaction from investors, with shares falling more than 15% in early trading.

Guidance Raises Concerns About Near-Term Growth

Investor concerns intensified after the company issued softer-than-expected guidance for upcoming quarters.
Hims & Hers expects second-quarter revenue to range between $680 million and $700 million while forecasting full-year revenue of up to $3 billion.
The company projected adjusted EBITDA of up to $55 million for the second quarter and as much as $350 million for the full year.
Analysts at Citigroup described the guidance as mixed and noted that the company’s outlook fell below some Wall Street expectations.
The weaker guidance reinforced concerns that the company is entering a more difficult transition period as it reshapes parts of its business model.

Weight Loss Drug Strategy Remains Under Pressure

A major focus for investors remains Hims & Hers’ role in the rapidly growing weight loss drug market.
The company recently reached an agreement with Novo Nordisk to sell branded GLP-1 weight loss treatments such as Wegovy through its platform.
As part of the arrangement, Hims agreed to stop promoting compounded copycat versions of the drugs.
The relationship between the companies had previously become contentious after Novo accused Hims of illegally marketing compounded alternatives to Wegovy.
Novo argued the practice raised significant patient safety concerns and threatened legal action earlier this year.
Hims later removed some compounded offerings following the dispute.

Compounded GLP-1 Drugs Drove Significant Growth

The controversy surrounding compounded GLP-1 drugs has been financially significant for Hims & Hers.
The company benefited from a regulatory loophole that allowed alternative manufacturers to sell versions of weight loss drugs during supply shortages.
Even after shortages eased, Hims continued offering compounded products, drawing criticism because the branded medications remain under patent protection until 2032.
The weight loss category has become one of the company’s most profitable and closely watched business segments, making any regulatory or partnership developments especially important for investors.
As the company shifts toward selling branded treatments instead of compounded alternatives, analysts are evaluating how the transition could affect margins, customer growth, and long-term profitability.

Investors Watching Transition Phase Closely

Management has acknowledged that the business is currently moving through a transition period as it adapts its strategy around GLP-1 medications and broader telehealth offerings.
The company’s future performance may increasingly depend on its ability to maintain subscriber growth while improving profitability and navigating tighter regulatory scrutiny.
Investors are also monitoring whether partnerships with major pharmaceutical firms can help stabilize revenue growth and reduce legal and reputational risks.
Despite continued demand for digital healthcare and weight loss treatments, the latest results suggest markets are becoming more cautious about the pace and sustainability of Hims & Hers’ expansion.